Getting your medical device approved shouldn’t take years of trial and error

I help early-stage MedTech founders get a clear EU MDR, UKCA and/or FDA regulatory strategy in just 30 days so they can move forward with confidence, reduce delays and get to market faster

The problem:
Many founders are unsure which pathway applies, what documents are required or how to avoid months of regulatory back-and-forth. Without a clear plan, they risk burning runway, missing opportunities and losing investor confidence

How I help:

- Map the exact regulatory pathway (CE, UKCA, 510(k), De Novo, PMA)
- Define intended use & classification to align with regulators
- Build a step-by-step submission readiness plan
- Provide hands-on support for technical documentation, QMS & audits
- Guide devices including SaMD, AI/ML, hardware and IVDs through IEC 62304, IEC 82304, applicable ISO standards and emerging AI frameworks

Full capabilities:

Regulatory consulting: CE marking under MDR/IVDR, UKCA certification, FDA pathways (510(k), De Novo, PMA). PRRC & UKRP services. Gap assessments, submission support & strategic planning

Quality assurance: Implement & remediate QMS to ISO 13485 & MDSAP. Lead audits, manage CAPAs & complaints, support risk management (ISO 14971), process validation (IQ, OQ, PQ) & sterilisation (ISO 11607). Certified ISO 13485 Lead Auditor (CQI/IRCA)

Digital health / SaMD: Compliance with IEC 62304, IEC 82304 & AI/ML frameworks. Software validation & CSV for regulatory alignment

eQMS platforms: Implement Greenlight Guru, Qualio, MasterControl, JIRA & Confluence, with CSV to ensure audit readiness

Due diligence: Regulatory & QMS assessments for investors, accelerators & M&A. Identify red flags in technical documentation & submissions before they become costly

Training & microconsulting: For teams & founders building internal capability. CQI/IRCA-registered tutor for MDR, IVDR, ISO 13485, ISO 14971 & MDSAP

I’m a startup advisor and competition judge for MedTech Innovator, Springboard Enterprises and MassChallenge. As a trainer and host of The MedTech Podcast, I work with founders, investors and accelerators worldwide to deliver regulatory clarity and practical strategies

I combine regulatory expertise with a practical, execution-focused mindset. Clients value my ability to cut through complexity, reduce time to market, pass audits and scale confidently, whether launching a first product or expanding internationally

If you’re navigating regulatory uncertainty or preparing for growth, let’s connect

🎙️ The MedTech Podcast | 📺 YouTube: @KarandeepBadwal

I told a startup CEO they needed a Quality Management System.  

Their response? "We'll give you a month to build it."  

Their FDA submission timeline? 6 months out.

I've worked with multiple medical device startups over the last few years. 

This conversation happens more often than you'd think.

Here's what most early-stage MedTech founders get dangerously wrong about QMS implementation:

1. They treat it like a checkbox exercise

A QMS isn't something you just buy and put in. It's the operational backbone that proves you can manufacture safely and consistently. 

The FDA may not review your QMS at submission but they will see it during inspection time!

2. They underestimate the real timeline

Minimum viable QMS for a Class II device: 3-6 months
Full implementation with training and evidence: 6-12 months
Trying to rush it in 30 days: Recipe for a 483 observation or worse

3. They confuse templates with compliance

You can download ISO 13485 templates in 10 minutes. But customizing them to YOUR specific device, YOUR processes and YOUR risk profile? That's where the real work lives.

4. They skip the most critical element

Design History File completeness. I've seen companies delay their 510k submission by 9-14 months because they didn't maintain proper design controls from day one. You can't retrofit this documentation credibly.

5. They don't budget for the hidden costs

QMS software: cost varies from 10k-100k+
Training and implementation: 40-60 hours of leadership time
External consulting: cost can vary
Ongoing maintenance: 10-15 hours monthly minimum

6. They build for today, not tomorrow

Your QMS needs to scale. What works for prototype builds won't survive commercial manufacturing. I've watched companies completely rebuild their QMS post-clearance because they didn't plan for growth.

I told this founder the truth: You can have a QMS in a month or you can have a COMPLIANT QMS that survives FDA scrutiny!

Pick one.

TAKEAWAY: Your QMS timeline should be built into your product development roadmap from day zero, not squeezed in before submission. The companies that get FDA clearance fastest are the ones who do it properly from day one.

What's the biggest misconception you've encountered about QARA in MedTech?

undefined undefined

Helping MedTech startups unlock EU CE Marking & US FDA strategy in just 30 days ⏳ | Regulatory Affairs Quality Consultant | ISO 13485 QMS | MDR/IVDR | Digital Health | SaMD | Advisor | The MedTech Podcast 🎙️

A fellow QARA professional new in their role called me in a panic.

Their CEO wanted to launch in Europe.

In 90 days.

With no regulatory strategy.........

I could have said it was impossible.

I could have turned them away.

Instead, I asked ONE question:

"What's driving this timeline?"

Turns out, they had a partnership opportunity that could change their entire business trajectory.

A major distributor wanted them at a European trade show.

But they needed CE marking first.

Here's what we did:

We didn't promise miracles.

We built a REALISTIC roadmap together.

We identified what could be fast-tracked and what couldn't.

We were brutally honest about the gaps.

The result?

They didn't make 90 days.

They made 193 days.

But that distributor waited.

Because we kept them informed every step of the way.

The partnership happened.

They're now generating over 40% of their revenue from Europe.

The lesson I learned that day changed how I approach every client conversation:

Urgency doesn't mean you abandon reality.

It means you get creative within the boundaries of what's actually possible.

Your job as a consultant isn't to be a miracle worker.

It's to be a TRUTH TELLER who finds the best path forward.

When a founder or CEO comes to you with an impossible timeline, how do you handle it?

Do you say yes to everything, or do you push back with solutions?

I just made a prediction that made a room full of investors uncomfortable

By 2027, AI won't just assist with regulatory submissions.

It will BE the regulatory pathway for certain device classes.

The FDA is already piloting it

Here's what I told them:

Right now, we're using AI to write summaries and check documents.

That's like using a calculator to add 2 plus 2.

We're missing the bigger picture.

Within three years, I believe we'll see:

Software-based devices getting real-time conditional approvals through AI-driven risk assessment engines.

Continuous monitoring replacing traditional post-market surveillance.

Predictive compliance scoring that flags issues BEFORE they become audit findings.

One investor pushed back hard.

"But the FDA moves slow. This will take decades."

I disagree.

The agency knows they're drowning in submissions.

510(k) review times keep climbing despite their best efforts.

They NEED this evolution as much as we do.

The MedTech companies preparing for this shift right now?

They're building data infrastructure that's AI-ready.

They're documenting in structured formats machines can interpret.

They're treating quality data like the strategic asset it actually is.

The ones waiting for the FDA to announce the change?

They'll spend 18 months playing catch-up while their competitors ship products.

I've been in regulatory affairs for over a decade.

I've never seen the landscape shift this fast.

The question isn't IF this happens.

It's whether your company will be ready when it does.

What's your take? Too aggressive a timeline or are we already behind?

I hit pause on the podcast for a few weeks....
 
Life and work had other plans, but I’m back at it starting Monday.
 
For those who haven’t tuned in yet: it’s The Medtech Podcast where I sit down with MedTech and digital health founders, operators, plus quality and regulatory experts to unpack what it really takes to build, get to market, stay compliant and scale. Expect practical lessons, real-world war stories and actionable takeaways you can apply straight away.
 
We’ve covered topics like AI/ML, SaMD, Female Health, Robotic Surgery etc. And I’m looking to bring on more voices from founders, leaders, clinical innovators, product leads and investors who’ve been in the trenches.
 
If you know someone doing interesting work in this space, drop their name below or shoot me a DM!
 
Looking forward to getting back behind the mic.

The Medtech Podcast

𝗗𝗲𝗰𝗲𝗻𝘁𝗿𝗮𝗹𝗶𝘀𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, 𝗵𝗼𝘄 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘄𝗼𝗿𝗸?

A snippet from The Medtech Podcast EP96 with Dr. med. (Univ. Tuzla) Amel Havkic, MBA, founder of EvoMed Consulting and a lung and critical care specialist, hospital clinical lead. Amel works at the intersection of bedside medicine and MedTech strategy, helping innovators build clinician-approved solutions that scale safely across real healthcare systems.

In this episode, we unpack why “clinicians love it” is rarely enough to win adoption, and what hospital purchasing actually looks like when procurement, IT, finance, compliance and workflows all have a seat at the table. Amel breaks down why switching away from legacy tools is painful, how integrations can break care pathways, and why solutions that feel like a natural part of the hospital ecosystem win faster. He also shares a practical lens for building frictionless implementation by aligning with standards like HL7, FHIR and DICOM, while proving measurable value for patients and payers.

We also go deep on decentralising healthcare. Amel explains how the Dutch model centralises high-end expertise while decentralising access through remote monitoring and home-based onboarding, and why this becomes a winning approach as staffing pressures rise. On AI, he makes the case for reframing it as augmented intelligence, not autonomy, and shows where decision support can raise the baseline of care by supporting clinicians in time-critical situations, as well as offloading admin burden that drains capacity.

Finally, Amel shares the thinking behind the EMC StarMap framework, a navigation tool built from real-world patterns of what makes MedTech succeed or fail. His core message is simple: regulatory approval is a milestone, but clinical adoption is the real finish line.

The whole podcast is available on all major platforms, including but not limited to Apple Podcasts and Spotify, via the following links:

Apple Podcasts: https://lnkd.in/d2F42zJT
Spotify: https://lnkd.in/dpejUHxt

If there are any particular guests or topics you would like us to cover in future episodes, then get in touch with Karandeep Singh Badwal

#TheMedTechPodcast #DigitalHealth #MedTechInnovation #ClinicalLeadership #HomeMonitoring #HealthcareSystems #MedicalTechnology

I help MedTech Leaders define their position in Healthcare Space | Creator of StarMap AI | Clinical Leader | Strategic Market Access & Patient Safety | International Speaker | Founder @ EvoMed Consulting

EvoMed Consulting

STOP pursuing FDA clearance. I told a client.......

They looked at me like I had three heads.

But here's the thing...

They were burning through money chasing 510(k) clearance for a device that could enter the market through a much faster pathway.

Their competitor was already selling.

While they were stuck in regulatory limbo.

Many founders think the FDA pathway is the fastest, cheapest and best.

It's not.

It's a BUSINESS DECISION.

And sometimes the "prestigious" route is just the expensive one.

Here's what smart MedTech companies do differently:

They explore ALL market entry options first.

They assess risk vs. speed vs. cost.

They don't let ego drive regulatory strategy.

They ask: "What's the fastest path to revenue?"

Not: "What sounds most impressive to investors?"

What is something nobody wants to hear?

Sometimes the best regulatory strategy is the one that gets you to market BEFORE your funding runs out.

Sometimes Class I is smarter than Class II.

Sometimes international first beats FDA first.

Your job isn't to impress people with your technology.

Your job is to get safe, effective devices into the hands of patients and clinicians.

Fast.

That CEO I mentioned?

They pivoted. Launched in six months instead of eighteen.

Now they're generating revenue while refining their FDA strategy.

Stop letting regulatory perfectionism kill your business momentum.

What's a regulatory "rule" in MedTech that you think needs to be challenged?

Many teams are still finalising their approach to EUDAMED.

With the database being built in phases, and 4 of its modules becoming mandatory in May 2026, it’s essential to understand what the system is designed to do, and what practical steps need to happen well before then.

EUDAMED aims to improve transparency and coordination on medical devices across the EU. It collects and connects data from six modules, providing visibility on everything from registration to surveillance.

This upcoming training/webinar will focus on what teams should prioritise now, before deadlines make action more difficult.

The session will help you:
→ Understand how EUDAMED fits into the MDR framework
→ Identify who needs to register, and how
→ Navigate what’s going live first
→ Prepare for actor registration and data requirements
→ Avoid common delays from real-world registration cases

I will walk through the structure, roles and required preparation, based on hands-on experience.

📍 Online
🗓️ Feb 24 at 11:00 CET
🎙️ Registration → https://lnkd.in/e4bHe2hc

Over a decade in MedTech Quality and Regulatory, I've watched this one mistake cost companies millions!

The SAME costly mistake destroy promising medical device companies over and over again.

They wait until the product is built to think about regulatory strategy.

Here's what actually happens when you do this:

Your engineering team designs an incredible device. Everyone is excited. You've spent 18 months and burned through funding.

Then you bring in regulatory.

And we tell you that based on your intended use, you need a 510k when you planned for exempt status. Or worse, you need clinical data you never budgeted for.

Now you're looking at 12-18 MORE months and another $500K minimum.

I just helped a client avoid this exact scenario last month.

We got involved at the concept stage. Worked with their team to refine the intended use and indications. Identified a predicate device BEFORE they finalized the design.

Result? They're on track for 510k clearance in 8 months instead of the 24+ month nightmare they were headed toward.

Here's my 5-point checklist for early-stage regulatory planning:

✓ Define your intended use and indications for use FIRST
✓ Determine your regulatory classification before finalizing design
✓ Identify predicate devices or clinical data requirements early
✓ Build your quality system AS you develop, not after
✓ Budget for regulatory from day one, not as an afterthought

The companies that succeed in MedTech don't have bigger budgets!

They have SMARTER planning.

What's the biggest regulatory surprise you've encountered in your MedTech journey?

Saving money on regulatory is a paradox. Why? 

Because when companies try to handle regulatory work retrospectively 

It ends up costing far more in both time and money

See my interview with Rashpal Singh Sagoo of BOXmedia 

Link in Comments

Is the EU MDR really that much of a hindrance to Medical Devices market approval, let me know your thoughts? 

#medicaldevices #innovation #prototyping #prototype #medical

I have been making content for a while now

My view is that we all have something to share

Regardless of our knowledge level we can provide value

I do get many asking me on how to start

I just tell them to not worry about making mistakes

I still make mistakes I even made one in this video 😀

See full interview in the comments!

#97 Beyond Ablation For Pain Management: Diagnostic-First FDA Strategy, Dual-Use Electrodes and the The Next Wave of Neurotechnology with Dave Rosa

Dave Rosa, CEO and President of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), medtech entrepreneur, board member and former executive at St. Jude Medical, Boston Scientific and C.R. Bard

Pleased to be featured as part of the upcoming Virtual VC Conf on 31 March 2026
 
The event brings together 100+ angels, VCs and family offices for a full day of online networking and conversations. If you’re raising, investing or just want to get closer to the VC ecosystem, worth checking out.
 
Free to attend, hosted by Max Pog  

Register: vcconf.com/?3623

Your FDA submission just got rejected.

Your champion swears they briefed leadership on the regulatory strategy.

But now you're hearing it's the first time the CEO has seen half of these requirements.

Sound familiar?

I've watched dozens of MedTech startups lose 6-12 months because they treated their Quality Manager like a champion when they were really just a main contact.

Here's how to build REAL regulatory champions who can actually move your device to market:

Step 1: Test Their Influence

Your Quality lead might love your strategy, but can they get the CEO to approve a 510k pivot? Can they push back when Engineering wants to skip design controls?

If they're nodding along but can't influence budget or timeline decisions, you don't have a champion yet.

Step 2: Arm Them With Executive Ammunition

I see this constantly. Founders send their internal Quality person a 40-page regulatory strategy deck and expect them to sell it upstairs.

Your champion needs a ONE PAGE summary that shows:
- Time to market impact
- Cost of delay vs cost of compliance
- Competitive risk of waiting

Make it so simple their CEO can forward it to the board.

Step 3: Don't Rely on One Person

The average FDA submission touches Engineering, Quality, Regulatory, Clinical and the C-suite. That's at least 5 stakeholders with different priorities.

Your Quality champion is critical, but if your VP of Engineering thinks regulatory is just paperwork, your timeline is doomed.

Build champions across functions early.

Step 4: Co-Create the Internal Strategy

Your champion knows the company politics. You know FDA expectations.

Don't just hand them a plan and hope they can navigate internal pushback on their own.

Schedule working sessions. Role-play the CFO objections. Prepare them for the "Can't we just do this faster?" questions.

Step 5: Map the REAL Decision Process

There's rarely one person who greenlights a regulatory pathway.

The CEO might have final say, but if your R&D Director thinks the testing requirements are overkill, they'll slow-walk everything.

Use your champion to identify who influences what, then build consensus from the bottom up.

The biggest mistake I see?

Treating your most engaged contact as your champion without testing if they can actually drive decisions.

Regulatory strategy doesn't fail in the documents.

It fails in the internal conversations you're not part of.

Who in your organization is your TRUE regulatory champion? Not just who attends the meetings, but who can move the needle when it counts?

Everyone says you need FDA clearance before you can talk to customers

That's backwards.

I see it all the time in MedTech. Founders spend 18-24 months in stealth mode, perfecting their device, navigating regulatory pathways, burning through capital.

Then they launch and discover the market doesn't actually want what they built.

The real risk is building something nobody will buy.

Here's what the best MedTech founders do differently:

They talk to hospitals, clinicians and procurement teams BEFORE finalizing their design. They validate the problem, the price point and the adoption barriers while they're still in development.

They use those conversations to shape their regulatory strategy, not the other way around.

Because here's the facts: your 510(k) pathway doesn't matter if you can't get on a hospital's GPO contract. Your CE Mark is worthless if clinicians won't change their workflow to use your device.

I've watched companies pivot their entire product strategy based on customer feedback gathered during development. They saved themselves from launching a commercially dead product with perfect regulatory documentation.

The regulatory pathway should support your commercial strategy.

Not define it.

Stop hiding behind regulatory timelines as an excuse to avoid the hard conversations with your actual customers.

The market will tell you what to build. Regulations will tell you how to build it safely.

Get the order right.

What's stopping you from talking to potential customers today?

One device platform can create multiple products without redesigning the entire system

A snippet from The Medtech Podcast EP97 with Dave Rosa, CEO and President of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), medtech entrepreneur, board member and former executive at St. Jude Medical, Boston Scientific and C. R. Bard GmbH. With three decades in medical devices and more than $200 million raised, Dave brings a rare mix of operator, inventor and capital markets experience to the future of neurotechnology and pain care.

In this episode, we unpack one of the biggest mistakes medtech companies make: building technology without enough real-world user feedback. Dave explains why innovation for the sake of innovation often fails, especially in larger companies, and why the best products are shaped by how physicians and patients actually use them. We also explore NeuroOne’s unique approach of combining diagnostics and therapeutics through the same electrode, and why that kind of multifunctional platform thinking can be both clinically powerful and commercially strategic.

A major theme in this conversation is regulatory strategy. Dave walks through NeuroOne’s deliberate “diagnostic first, therapeutic second” FDA pathway, explaining why starting with an easier regulatory indication can de-risk the technology, shorten timelines and create a stronger platform for later therapeutic claims. We also discuss the value of reusing the same generator across multiple indications, how founders often wait too long to engage with FDA, and why platform leverage matters from both a business and development perspective.

We also go deep on chronic pain and lower back pain. Dave shares why today’s pain solutions often fall short, how different triggers require different treatment approaches, and where technologies like ablation, stimulation and smarter electrode design could shift outcomes. He also highlights how seemingly small user-experience issues, like frequent recharging, can destroy patient adherence and wipe out billions in company value.

The whole podcast is available on all major platforms, including but not limited to Apple Podcasts and Spotify, via the following links:

Apple Podcasts: https://lnkd.in/d2F42zJT
Spotify: https://lnkd.in/dpejUHxt

If there are any particular guests or topics you would like us to cover in future episodes, then get in touch with Karandeep Singh Badwal

#MedTech #MedicalDevices #HealthTech #MedicalInnovation #RegulatoryStrategy #StartupLessons #DigitalHealth #MedTechFounder

28 April 2026 is coming fast

The UK’s new clinical trials regulations go live on 28 April 2026 and they will change how we handle trial set-up, approvals and substantial modifications.

Medicines and Healthcare products Regulatory Agency MHRA is running a webinar with the Health Research Authority HRA on 12 March (2–4pm GMT) focused on practical implementation for sponsors, researchers and industry stakeholders.

If you are involved in CTIMPs, this looks worth attending for 3 reasons:
• Clarity on transitional arrangements and what “good” looks like during the switch
• A deep dive on Route B substantial modifications (including how it’s expected to work in practice)
• Live Q&A, which is usually where the real nuances come out

My takeaway: if your SOPs, templates and internal decision trees for modifications are still based on the old way of working, now is the time to update them and train teams, not in late April!

Are you ready for Route B and the new end-to-end process? What’s the one area you are tightening up before 28 April?

link: https://lnkd.in/eiruS8Jr

Thanks Pav Singh for sharing

#ClinicalTrials #MHRA #HRA #CTIMPs #UKResearch #RegulatoryAffairs #ClinicalOperations #Pharma #Biotech

eventbrite.co.uk

Clinical Trials Regulations: Countdown to implementation

Medicines and Healthcare products Regulatory Agency

Health Research Authority

Technical Director - Construction Design, HSEQ & Asset Optimisation | CEng MICE CMIOSH PISEP CMaPS | Hon. Ass. Professor - Engineering @UOB | PhD Researcher Robotics Autonomous Systems - Regulations, Standards & Ethics.

From April 2026, NICE plans to bring digital and AI health technologies into the same statutory appraisal and adoption pathway as medicines.

That means if NICE - National Institute for Health and Care Excellence issues positive guidance, NHS organisations may have a legal duty to fund and adopt, often within 90 days.

An important discussion for anyone involved in digital health adoption across the NHS.

Link - https://lnkd.in/e38CEp5e

#DigitalHealth #NHS #NICE #HealthTech #AIinHealthcare

🎉 Do the tasks and responsibilities which have been assigned to you and that you are suitably competent in 🩺🧪

Picture this: auditors are observing operators diligently to ensure they are following the standard operating procedures (SOPs) and work instructions.

It's like watching a symphony of precision and compliance! 

But hold on, don't let the word "audit" scare you off. 

Remember, as long as you're following those SOPs and work instructions, it's smooth sailing!

💡 Here's a tip: make sure you're competent in what you do, whether it's through experience, training or a combination of both. 

You're the master of your craft! And guess what? Competence is your shield against any audit woes.

🤔 Now, what if the auditors veer into unfamiliar territory and ask about something outside your scope of work? 

Don't panic! Remember, it's perfectly okay to point it out and redirect them to the right personnel, just a simple

"That's a job for our fantastic colleagues in XYZ department!" 

📖 For those interested in the history: "Genkuro Yoshitsune to Musashibo Benkei." Minamoto no Yoshitsune (1159 - June 15, 1189) was a general of the Minamoto clan of Japan in the late Heian and early Kamakura period. "It is evident that Yoshitsune had a genius for offensive warfare...and although Yoshitsune had no knowledge of naval warfare he had the advantage of an acute strategic insight and a quick eye for tactical chances." He is considered one of the greatest and the most popular warriors of his era, and one of the most famous samurai fighters in the history of Japan. Musashibo Benkei (1155-1189), popularly called Benkei, was a Japanese warrior monk who served Minamoto no Yoshitsune. He is commonly depicted as a man of great strength and loyalty and a popular subject of Japanese folklore. 𝗪𝗼𝗼𝗱𝗰𝘂𝘁 𝗯𝘆 𝗧𝗼𝘆𝗼𝗸𝘂𝗻𝗶 𝗨𝘁𝗮𝗴𝗮𝘄𝗮, 𝗰𝗶𝗿𝗰𝗮 𝟭𝟴𝟬𝟰-𝟭𝟴.

#QualityManagement #MedicalDeviceManufacturing #QMS #MedicalDevices

Many medical devices will not fail because of innovation
 
They will fail because their EU MDR transition was left too late
 
The companies that act now will keep market access
 
The ones who delay may lose it
 
Is the industry really ready?
 
#EUMDR #MedicalDevices #RegulatoryAffairs

taplio

Karandeep Badwal's Linkedin Analytics

Karandeep Badwal

Performance ScoreKarandeep Badwal's LinkedIn Performance

What is Karandeep talking about?

Who is engaging with Karandeep

Karandeep Badwal's Best Posts (last 30 days)

Ready to grow your LinkedIn presence?